NRx Pharmaceuticals Inc.
NRXP | NASDAQ
$3.29
-$0.03 (-0.90%)
At close: Sep 21, 2026, 4:00 PM ET
$3.29
$0 (0.00%)
Pre-market:
Sep 22, 2026, 7:26 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.23M | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 505K | 5K | 5K | 4K | 2K | 2K |
Gross Profit | 720K | -5K | -5K | -4K | -2K | -2K |
Operating Income | -16.22M | -19.7M | -27.59M | -44.34M | -95.2M | -22.06M |
Interest Income | 12K | 44K | 494K | 249K | 18 | 56 |
Pretax Income | -28.62M | -25.13M | -30.15M | -39.75M | -93.06M | -51.78M |
Net Income | -28.62M | -25.13M | -30.15M | -39.75M | -93.06M | -51.78M |
Selling & General & Admin | 13.06M | 13.5M | 14.21M | 27.3M | 74.94M | 11.43M |
Research & Development | 3.78M | 6.2M | 13.37M | 17.03M | 20.26M | 10.63M |
Other Expenses | 106K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 16.94M | 19.7M | 27.58M | 44.33M | 95.2M | 22.06M |
Interest Expense | 671K | 1.08M | 120K | n/a | 18K | 56K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 17.45M | 19.7M | 27.59M | 44.34M | 95.2M | 22.06M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.4M | 10.52M | 7.58M | 65.77M | 46.92M | 546.59K |
Shares Outstanding (Diluted) | 21.4M | 10.52M | 7.58M | 65.77M | 46.92M | 546.59K |
EPS (Basic) | -1.34 | -2.39 | -3.98 | -0.60 | -7.44 | -1.51 |
EPS (Diluted) | -1.34 | -2.39 | -3.98 | -0.60 | -7.44 | -1.51 |
EBITDA | -27.81M | -24.04M | -30.03M | -39.75M | -93.04M | -51.72M |
EBIT | -27.95M | -24.05M | -30.03M | -39.75M | -93.05M | -51.72M |
Depreciation & Amortization | 143K | 5K | 5K | 4K | 2K | 2K |
Add to Watchlist
Select watchlists to add or remove NRXP